Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00672984 · ClinicalTrials.gov registry record · Phase 1

Guanfacine Immediate-release Electrocardiogram Results (QTc) Study

A Phase 1 study of Healthy Volunteers, sponsored by Shire.

Completed
Registry status
Phase 1
Development phase
83
Enrollment target
1
Study location

NCT00672984: Completed Phase 1 study of Healthy Volunteers, sponsored by Shire.

NCT00672984 is a Phase 1 study of Healthy Volunteers that has completed, run by Shire. The registered enrollment target is 83 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00672984, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Shire.

COMPLETED
Registry status
Phase 1
Development phase
83 participants
Enrollment target
1
Study location

Study Summary

To assess the effect of immediate-release guanfacine hydrochloride, administered at therapeutic and supratherapeutic doses, on QT/QTc in healthy normal males and females

Primary Outcome

QTcNi is the QT interval using a subject-specific correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG moxifloxacin
  • DRUG immediate release guanfacine hydrochloride

Study Locations (1)

Washington

  • Charles River Clinical Services Northwest, Inc. - Tacoma

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2008-04-18
Est. Completion 2008-08-07
Phase Phase 1
Shire

245 total trials

What the finished NCT00672984 record still lists

NCT00672984 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00672984 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT00672984 about?

NCT00672984 is a clinical study titled "Guanfacine Immediate-release Electrocardiogram Results (QTc) Study". To assess the effect of immediate-release guanfacine hydrochloride, administered at therapeutic and supratherapeutic doses, on QT/QTc in healthy normal males and females

What is the current status of trial NCT00672984?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2008-04-18. Estimated completion is 2008-08-07.

What conditions does trial NCT00672984 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT00672984?

The interventions under investigation include: Placebo (DRUG), moxifloxacin (DRUG), immediate release guanfacine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00672984?

This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00672984 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00672984's enrollment target sits among peer trials

83 85th of 283 higher than 199 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02974647 · 83 participants · Phase 2

    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

  • NCT03919292 · 83 participants · Phase 1

    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

  • NCT04626674 · 83 participants · Phase 1

    A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  • NCT05277168 · 83 participants · Phase 1

    A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00672984, the US trial registry maintained by the National Library of Medicine. NCT00672984 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.